CVRx (CVRX) investor relations material

Leadership transition

• CFO Jared Oasheim announced his intention to transition out, with a structured process for succession and a commitment to remain for 9–10 months and support onboarding his successor.

• The transition is designed to ensure continuity and maintain company momentum during the search and onboarding of a new CFO.

Market opportunity and strategy

• Barostim therapy targets heart failure patients with reduced ejection fraction, focusing on a subset with specific biomarkers and symptoms.

• The annual U.S. incidence is estimated at 76,000 patients ($2.4B), with a prevalence pool of 340,000 ($10B), and potential to triple with expanded indications.

• Go-to-market strategy revised 18 months ago, emphasizing targeted sales teams, deep engagement with high-potential centers, and overcoming adoption barriers.

Clinical evidence and adoption

• BeAT-HF pivotal trial demonstrated safety and significant quality-of-life improvements, though COVID-19 limited full enrollment for hospitalization and mortality endpoints.

• Real-world evidence now shows an 85% reduction in hospitalizations and positive impacts on arrhythmia, kidney function, and diuresis.

• Recent Heart Failure Society of America consensus supports device therapy consideration after six months of medical therapy.